Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
KKR's Healthcare Royalty affiliate (HCRx) entered a $105 million non-recourse royalty financing agreement with Spero Therapeutics, securing rights to a portion of future milestones and royalties for the drug Utebzi. The financing provides Spero with non-dilutive capital to support the Phase 2 development of its immunology drug candidate SP001, extending Spero's cash runway into the second half of 2029.
Key figures
- Deal Value Usd
- 105000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.